MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-06-2023
NanoString Technologies ROE Ratio 2011-2026 | NSTG
Annual ROE Ratio NanoString Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -348.24 | -65.13 | -35.86 | -39.07 | -209.93 | -108.61 | -382.68 | -225.48 | -111.66 | -93.05 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -35.86 | -382.68 | -161.97 |
Quarterly ROE Ratio NanoString Technologies
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.56 | -187.79 | -426.09 | -106.26 | -121.96 | -93.41 | -70.88 | -39.72 | -46.66 | -37.91 | -34.45 | -28.37 | -5.34 | -20.23 | -30.63 | -39.07 | -119.36 | -142.24 | -178.88 | -209.93 | -174.49 | -158.21 | -113.69 | -108.61 | -181.0 | -234.56 | -311.01 | -382.68 | -360.11 | -324.96 | -298.51 | -253.52 | -209.5 | -189.77 | -159.85 | -111.66 | -112.08 | -109.44 | -95.47 | -93.05 | -56.59 | -27.15 | -5.88 | 17.19 | 8.79 | 3.81 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.19 | -426.09 | -131.54 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
1.11 | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.44 | -16.64 % | $ 5.04 M | Israel |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 10.14 | -0.29 % | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-48.89 | $ 2.96 | -1.0 % | $ 252 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Citius Pharmaceuticals
CTXR
|
-56.26 | $ 0.86 | 0.67 % | $ 5.79 M | USA |
 |
Cue Biopharma
CUE
|
-100.64 | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-34.54 | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
Daré Bioscience
DARE
|
-471.37 | $ 1.81 | 4.02 % | $ 20.2 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-87.07 | $ 20.36 | -3.32 % | $ 2.84 B | France |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-597.58 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |